​

Acelyrin (SLRN) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

SLRN Stock Forecast

Acelyrin stock forecast is as follows: an average price target of $10.50 (represents a 233.33% upside from SLRN’s last price of $3.15) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

SLRN Price Target

The average price target for Acelyrin (SLRN) is $10.50 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $6.00. This represents a potential 233.33% upside from SLRN's last price of $3.15.

SLRN Analyst Ratings

Buy

According to 14 Wall Street analysts, Acelyrin's rating consensus is 'Buy'. The analyst rating breakdown for SLRN stock is 0 'Strong Buy' (0.00%), 7 'Buy' (50.00%), 7 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Acelyrin Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Derek ArchilaWells Fargo$15.00$5.72162.24%376.19%
Aug 14, 2024Samantha SemenkowCitigroup$6.00$4.0647.78%90.48%
Mar 20, 2024Derek ArchilaWells Fargo$13.00$8.3256.25%312.70%

The latest Acelyrin stock forecast, released on Oct 16, 2024 by Derek Archila from Wells Fargo, set a price target of $15.00, which represents a 162.24% increase from the stock price at the time of the forecast ($5.72), and a 376.19% increase from SLRN last price ($3.15).

Acelyrin Price Target by Period

1M3M12M
# Anlaysts-13
Avg Price Target-$15.00$11.33
Last Closing Price$3.15$3.15$3.15
Upside/Downside-100.00%376.19%259.68%

In the current month, the average price target of Acelyrin stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Acelyrin's last price of $3.15. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 14, 2024Cowen & Co.BuyBuyHold
Oct 16, 2024Wells FargoOverweightOverweightHold
Sep 25, 2024Piper SandlerOverweightOverweightHold
Aug 14, 2024Cowen & Co.BuyBuyHold
Aug 14, 2024CitigroupNeutralNeutralHold
Aug 14, 2024Piper SandlerOverweightOverweightHold
Aug 14, 2024H.C. WainwrightBuyNeutralDowngrade
Jul 08, 2024Wells FargoOverweightUpgrade
May 24, 2024Piper SandlerOverweightOverweightHold
May 10, 2024H.C. WainwrightBuyBuyHold
May 30, 2023Deutsche BankHoldInitialise
May 30, 2023Craig-HallumBuyInitialise
May 30, 2023Goldman SachsNeutralInitialise
May 30, 2023UBSNeutralInitialise
May 30, 2023RBC CapitalOutperformInitialise
May 30, 2023Morgan StanleyEqual-WeightInitialise
May 30, 2023NeedhamBuyInitialise
May 30, 2023William BlairOutperformInitialise
May 30, 2023Cowen & Co.OutperformInitialise
May 30, 2023Exane BNP ParibasNeutralInitialise
May 30, 2023CitigroupOverweightInitialise
May 30, 2023Piper SandlerOverweightInitialise

Acelyrin's last stock rating was published by Cowen & Co. on Nov 14, 2024. The company gave SLRN a "Buy" rating, the same as its previous rate.

Acelyrin Financial Forecast

Acelyrin Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Acelyrin's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SLRN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Acelyrin EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict SLRN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acelyrin's previous annual EBITDA (undefined) of $NaN.

Acelyrin Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-134.78M$-60.90M$-58.90M$-60.90M$-62.23M$-53.18M$-47.61M$-45.02M$-84.61M$-79.74M$-77.35M
High Forecast$-134.78M$-60.90M$-58.90M$-60.90M$-62.23M$-53.18M$-47.61M$-45.02M$-69.23M$-79.74M$-77.35M
Low Forecast$-134.78M$-60.90M$-58.90M$-60.90M$-62.23M$-53.18M$-47.61M$-45.02M$-99.04M$-79.74M$-77.35M
Surprise %-----------

Acelyrin's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLRN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Acelyrin SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Acelyrin's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SLRN last annual SG&A of $NaN (undefined).

Acelyrin EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-1.35$-0.61$-0.59$-0.61$-0.62$-0.53$-0.48$-0.45$-0.85$-0.80$-0.78
High Forecast$-1.35$-0.61$-0.59$-0.61$-0.62$-0.53$-0.48$-0.45$-0.69$-0.80$-0.78
Low Forecast$-1.35$-0.61$-0.59$-0.61$-0.62$-0.53$-0.48$-0.45$-0.99$-0.80$-0.78
Surprise %-----------

According to undefined Wall Street analysts, Acelyrin's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLRN previous annual EPS of $NaN (undefined).

SLRN Forecast FAQ

Is Acelyrin a good buy?

Yes, according to 14 Wall Street analysts, Acelyrin (SLRN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 50.00% of SLRN's total ratings.

What is SLRN's price target?

Acelyrin (SLRN) average price target is $10.5 with a range of $6 to $15, implying a 233.33% from its last price of $3.15. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Acelyrin stock go up soon?

According to Wall Street analysts' prediction for SLRN stock, the company can go up by 233.33% (from the last price of $3.15 to the average price target of $10.5), up by 376.19% based on the highest stock price target, and up by 90.48% based on the lowest stock price target.

Can Acelyrin stock reach $5?

SLRN's average twelve months analyst stock price target of $10.5 supports the claim that Acelyrin can reach $5 in the near future.

What are Acelyrin's analysts' financial forecasts?

Acelyrin's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-208M (high $-208M, low $-208M), average SG&A $0 (high $0, low $0), and average EPS is $-2.084 (high $-2.084, low $-2.084). SLRN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-315M (high $-315M, low $-315M), average SG&A $0 (high $0, low $0), and average EPS is $-3.16 (high $-3.16, low $-3.16).